PubRank

Jacques Morel

Author PubWeight™ 34.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009 2.73
2 Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014 2.36
3 A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the 'FLARE' instrument. Ann Rheum Dis 2011 1.77
4 Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis Rheumatol 2014 1.71
5 The TNF family member APRIL dampens collagen-induced arthritis. Ann Rheum Dis 2012 1.49
6 Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012 1.18
7 Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS One 2013 1.02
8 Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005 0.98
9 TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011 0.96
10 Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014 0.95
11 Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 2010 0.92
12 Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies. Clin Exp Rheumatol 2012 0.92
13 Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine 2010 0.88
14 Scurvy as the presenting illness of Whipple's disease exacerbated by treatment with etanercept in a patient with ankylosing spondylitis. J Rheumatol 2010 0.88
15 Whipple's disease diagnosed during biological treatment for joint disease. Joint Bone Spine 2010 0.86
16 Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008 0.85
17 The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine 2013 0.85
18 Lymphotoxin α revisited: general features and implications in rheumatoid arthritis. Arthritis Res Ther 2011 0.84
19 Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 2013 0.84
20 Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 2011 0.84
21 Tocilizumab: therapy and safety management. Joint Bone Spine 2010 0.82
22 Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2013 0.82
23 Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies. Curr Pharm Des 2014 0.82
24 Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine 2010 0.82
25 Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012 0.81
26 Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis. Joint Bone Spine 2006 0.81
27 Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol 2012 0.81
28 Mesenteric and splenic cat-scratch disease during etanercept therapy. Rheumatology (Oxford) 2009 0.81
29 High levels of memory B cells are associated with response to a first tumor necrosis factor inhibitor in patients with rheumatoid arthritis in a longitudinal prospective study. Arthritis Res Ther 2014 0.80
30 Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Joint Bone Spine 2010 0.80
31 AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid 2015 0.78
32 Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2007 0.77
33 Abatacept therapy and safety management. Joint Bone Spine 2009 0.77
34 To target or not to target APRIL in systemic lupus erythematosus: that is the question! Arthritis Res Ther 2013 0.76
35 Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum 2011 0.76
36 Distinct effects of soluble and membrane-bound fas ligand on fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheumatol 2014 0.75
37 Rheumatic and musculoskeletal features of Whipple disease: a report of 29 cases. J Rheumatol 2013 0.75
38 Pulsed erbium fiber laser with an acetylene-filled photonic crystal fiber for saturable absorption. Opt Lett 2011 0.75
39 [Classification criteria for rheumatoid arthritis]. Rev Prat 2012 0.75
40 All-fiber frequency-stabilized erbium doped ring laser. Opt Express 2010 0.75
41 Unusual case of spondylodiscitis due to Staphylococcus saccharolyticus. Joint Bone Spine 2005 0.75
42 Etanercept normalises left ventricular mass in patients with rheumatoid arthritis. Ann Rheum Dis 2012 0.75
43 On the AJR viewbox. Pseudotumoral colonic tuberculosis complicating rheumatoid arthritis treated with a tumor necrosis factor antagonist. AJR Am J Roentgenol 2006 0.75
44 Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients. Joint Bone Spine 2012 0.75
45 On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Joint Bone Spine 2011 0.75
46 Efficacy of rituximab in a patient with lupus nephritis despite low levels of CD19. Rheumatology (Oxford) 2010 0.75
47 [Towards Unity for Health" criteria applied to medical centers in Belgium]. Educ Health (Abingdon) 2007 0.75
48 First investigation of the noise and modulation properties of the carrier-envelope offset in a modelocked semiconductor laser. Opt Lett 2016 0.75
49 [Postoperative discitis due to Propionibacterium acnes]. Presse Med 2010 0.75